Human myocardial mitochondrial oxidative capacity is impaired in mild acute heart transplant rejection.
Acute cellular heart transplant rejection
Heart failure
Mitochondrial respiration
Myocardial inflammation
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
19
08
2021
received:
29
06
2021
accepted:
24
08
2021
pubmed:
8
9
2021
medline:
22
3
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
Acute cellular rejection (ACR) following heart transplantation (HTX) is associated with long-term graft loss and increased mortality. Disturbed mitochondrial bioenergetics have been identified as pathophysiological drivers in heart failure, but their role in ACR remains unclear. We aimed to prove functional disturbances of myocardial bioenergetics in human heart transplant recipients with mild ACR by assessing myocardial mitochondrial respiration using high-resolution respirometry, digital image analysis of myocardial inflammatory cell infiltration, and clinical assessment of HTX patients. We hypothesized that (i) mild ACR is associated with impaired myocardial mitochondrial respiration and (ii) myocardial inflammation, systemic oxidative stress, and myocardial oedema relate to impaired mitochondrial respiration and myocardial dysfunction. We classified 35 HTX recipients undergoing endomyocardial biopsy according International Society for Heart and Lung Transplantation criteria to have no (0R) or mild (1R) ACR. Additionally, we quantified immune cell infiltration by immunohistochemistry and digital image analysis. We analysed mitochondrial substrate utilization in myocardial fibres by high-resolution respirometry and performed cardiovascular magnetic resonance (CMR). ACR (1R) was diagnosed in 12 patients (34%), while the remaining 23 patients revealed no signs of ACR (0R). Underlying cardiomyopathies (dilated cardiomyopathy 50% vs. 65%; P = 0.77), comorbidities (type 2 diabetes mellitus: 50% vs. 35%, P = 0.57; chronic kidney disease stage 5: 8% vs. 9%, P > 0.99; arterial hypertension: 59% vs. 30%, P = 0.35), medications (tacrolimus: 100% vs. 91%, P = 0.54; mycophenolate mofetil: 92% vs. 91%, P > 0.99; prednisolone: 92% vs. 96%, P > 0.99) and time post-transplantation (21.5 ± 26.0 months vs. 29.4 ± 26.4 months, P = 0.40) were similar between groups. Mitochondrial respiration was reduced by 40% in ACR (1R) compared with ACR (0R) (77.8 ± 23.0 vs. 128.0 ± 33.0; P < 0.0001). Quantitative assessment of myocardial CD3 Mild ACR with inflammatory cell infiltration associates with impaired mitochondrial bioenergetics in cardiomyocytes. Our findings may help to identify novel checkpoints in cardiac immune metabolism as potential therapeutic targets in post-transplant care.
Identifiants
pubmed: 34490749
doi: 10.1002/ehf2.13607
pmc: PMC8712779
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4674-4684Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Heart Lung Transplant. 2010 Aug;29(8):914-56
pubmed: 20643330
Biofactors. 1999;9(2-4):301-6
pubmed: 10416044
Transplant Direct. 2020 Oct 19;6(11):e616
pubmed: 33134492
J Cardiovasc Magn Reson. 2017 Mar 29;19(1):38
pubmed: 28351402
Heart Fail Rev. 2017 Jul;22(4):431-440
pubmed: 28497231
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Heart Lung Transplant. 2008 Sep;27(9):943-56
pubmed: 18765186
J Am Heart Assoc. 2021 Jul 6;10(13):e019995
pubmed: 34169737
J Mol Cell Cardiol. 2000 Dec;32(12):2361-7
pubmed: 11113011
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):593-608
pubmed: 28956198
Methods Mol Biol. 2012;810:25-58
pubmed: 22057559
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
J Heart Lung Transplant. 2001 May;20(5):497-502
pubmed: 11343975
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
Circulation. 1996 Sep 15;94(6):1334-8
pubmed: 8822989
Antioxid Redox Signal. 2008 Jun;10(6):1031-40
pubmed: 18327972
J Clin Med. 2020 Nov 06;9(11):
pubmed: 33172082
ESC Heart Fail. 2021 Dec;8(6):4674-4684
pubmed: 34490749
Int J Biochem Cell Biol. 2009 Oct;41(10):1837-45
pubmed: 19467914
N Engl J Med. 2007 Mar 15;356(11):1140-51
pubmed: 17360992
Cardiovasc Pathol. 2009 Jul-Aug;18(4):198-204
pubmed: 18619859
Adv Exp Med Biol. 2017;982:191-202
pubmed: 28551788
Clin Exp Immunol. 1991 Mar;83(3):447-51
pubmed: 1672270
Virchows Arch A Pathol Anat Histopathol. 1993;423(3):157-60
pubmed: 7901937
Front Endocrinol (Lausanne). 2020 Aug 19;11:546
pubmed: 32973679
Arch Mal Coeur Vaiss. 1991 Jun;84(6):855-9
pubmed: 1898220
Cardiovasc Res. 2008 Jul 15;79(2):331-40
pubmed: 18339649
Circulation. 2004 Aug 24;110(8):894-6
pubmed: 15326079
Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(1):H124-H140
pubmed: 31074651
J Cardiovasc Transl Res. 2019 Apr;12(2):107-115
pubmed: 29589269
Eur J Heart Fail. 2014 Oct;16(10):1066-72
pubmed: 25163698
Heart Fail Rev. 2002 Apr;7(2):115-30
pubmed: 11988636
Diabetes. 2018 Dec;67(12):2695-2702
pubmed: 30257974
Cent Eur J Immunol. 2014;39(1):109-15
pubmed: 26155110
Am J Physiol Heart Circ Physiol. 2013 Jun 1;304(11):H1407-14
pubmed: 23542918
Oxid Med Cell Longev. 2021 Feb 16;2021:8049079
pubmed: 33643519
Circ Res. 2014 Jul 18;115(3):348-53
pubmed: 24874428
Cardiovasc Res. 2016 Sep;111(4):338-47
pubmed: 27450980
Exp Mol Med. 2019 Feb 14;51(2):1-10
pubmed: 30765687
Heart Fail Rev. 2013 Nov;18(6):673-81
pubmed: 23096264
Eur J Heart Fail. 2013 Feb;15(2):150-7
pubmed: 23115323
Curr Cardiovasc Imaging Rep. 2015;8(3):6
pubmed: 25705323
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11389-94
pubmed: 26217001
Transplantation. 1990 Nov;50(5):751-5
pubmed: 2238049
J Heart Lung Transplant. 2019 Oct;38(10):1056-1066
pubmed: 31548031
J Heart Lung Transplant. 2005 Nov;24(11):1710-20
pubmed: 16297770
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
J Cardiovasc Magn Reson. 2009 Dec 30;11:56
pubmed: 20042111